Alkermes plc (ALKS) Stock

Healthcare · Drug Manufacturers - Specialty & Generic · Member of Other US Stocks

Alkermes plc (ALKS) closed at USD 39.08 on 2026-10-14, a change of +26.1 % over the past year, with a market capitalization of USD 6.73B.

Alkermes plc recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Alkermes plc key figures

Previous close

USD 39.08 (2026-10-14)

1-year change

+26.1 %

Market cap

USD 6.73B

Enterprise value

USD 7.64B

P/E ratio (trailing)

105.53

P/E ratio (forward)

22.18

EPS (trailing)

0.38

EPS (forward)

1.81

PEG ratio

1.96

Price to book

3.71

Revenue growth

27 %

Earnings growth

-99.4 %

Dividend per share (trailing)

0.00

Short ratio

8.24

Employees

2,050

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Alkermes plc

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Alkermes plc and compare it with other stocks.